Hypothyroidism and dyslipidemia: Modern concepts and approaches

Current Cardiology Reports

Volumn 6, Issue 6, 2004, Pages 451-456

  Pearce, Elizabeth N ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; GC 1; GCS 23425; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR AFFECTING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; REVIEW; THYROTOXICOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 9744263284     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0054-3     Document Type: Review

References (49)

1. Mason RL, Hunt HM, Hurxthal L: Blood cholesterol values in hyperthyroidism and hypothyroidism. N Engl J Med 1930, 203: 273-1278.
2. Hollowell JG, Staehling NW, Flanders WD, et al.: Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87:489-499.
3. Sawin CT, Castelli WP, Hershman JM, et al.: The aging thyroid: Thyroid deficiency and the Framingham Study. Arch Intern Med 1985, 145:1386-1388.
4. Vanderpump MJP, Tunbridge WMG, French JM, et al.: The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995, 43: 5-68.
5. Choi JW, Choi HS: The regulatory effects of thyroid hormone on the activity of 3-hydroxy-3-methylglutaryl coemzyme A reductase. Endocr Res 2000, 26:1-21.
6. Shin DJ, Osborne TF: Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem 2003, 278: 4114-34118.
7. Tan KCB, Shiu SWM, Kung AWC: Plasma cholsteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab 1998, 83:140-143.
8. Lam KS, Chan MK, Yeung RT: High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction - effects of treatment. Q J Med 1986, 59: 13-521.
9. Pauletzki J, Stellaard F, Paumgartner G: Bile acid metabolism in human hyperthyroidism. Hepatology 1989, 9: 52-855.
10. Boberg J, Dahlberg PA, Vessby B, Lithell H: Serum lipoprotein and apolipoprotein concentrations in patients with hyperthyroidism and the effect of treatment with carbimazole. Acta Med Scand 1984, 215:453-459.
11. O'Brien T, Dineen SF, O'Brien PC, Palumbo PJ: Hyperlipidemia in patients with primary and secondary hypothyroidism. May Clin Proc 1993, 68:860-866.
12. Kuusi T, Taskinen MP, Nikkila EA: Lipoproteins, lipolytic enzymes and hormonal status in hypothyroid women at different levels of substitution. J Clin Endocrinol Metab 1988, 66:51-56.
13. Martinez-Triguero ML, Hernandez-Mijares A, Nguyen TT, et al.: Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998, 73:837-841.
14. Bakker SJL, ter Maaten JC, Popp-Snijders C, et al.: The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001, 86:1206-1211.
15. Müller B, Zulewski H, Huber P, et al.: Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. N Engl J Med 1995, 333:964-969.
16. Packard CJ, Shepherd J, Lindsay GM, et al.: Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab 1993, 76:1209-1216.
17. Agdeppa D, Macaron C, Mallik T, Schnuda ND: Plasma high density lipoprotein cholesterol in thyroid disease. J Clin Endocrinol Metab 1979, 49:726-729.
18. Aviram M, Luboshitzky R, Brook JG: Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. Clin Biochem 1982, 15:62-66.
19. Lithell H, Boberg J, Hellsing K, et al.: Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy. Eur J Clin Invest 1981, 11: -10.
20. Tanis BC, Westendorp GJ, Smelt HM: Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol 1996, 44:643-649.
21. Vierhapper H, Nardi A, Grosser P, et al.: Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000, 10:981-984.
22. Kanaya AM, Harris F, Volpato S, et al.: Association between thyroid dysfunction and total cholesterol level in an older biracial population: the Health, Aging, and Body Composition Study. Arch Intern Med 2002, 162:773-779.
23. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC: The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000, 160: 26-534.
24. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulis M: Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000, 10:803-808.
25. Kong WM, Sheikh MH, Lumb PJ, et al.: A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002, 112:348-354.
26. Carracio N, Ferrannini E, Morizani F: Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002, 87:1533-1538.
27. Meier C, Staub JJ, Roth CB, et al.: TSH-controlled L-thyroxine therapy reduced cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86:4860-4866.
28. Danese MD, Ladenson PW, Meinert CL, et al.: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000, 85:2993-3001.
29. Monzani F, Caraccio N, Kozakowa M, et al.: Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2004, 89:2099-2106.
30. Nagasaki T, Inaba M, Henmi Y, et al.: Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function. Clin Endocrinol 2003, 59: 07-612.
31. Hak AE, Pols HAP, Visser TJ, et al.: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 2000, 132:270-278.
32. Pazos F, Alvarez JJ, Rubies-Prat J, et al.: Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 1995, 80: 62-566.
33. Milionis HJ, Efstathiadou Z, Tselepis AD, et al.: Lipoprotein(a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid 2003, 13:365-369.
34. Tan KCB, Shiu SWM, Kung AWC: Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998, 83:2921-2924.
35. O'Brien T, Katz K, Hodge D, et al.: The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII, and E. Clin Endocrinol 1997, 46: 7-20.
36. Weintraub M, Grosskopf I, Trostanesky Y, et al.: Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab 1999, 84:2532-2536.
37. Ito M, Takamatsu J, Matsuo T, et al.: Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinol 2003, 58: 21-626.
38. Sundaram V, Hanna HF, Koneru L, et al.: Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab 1997, 82:3241-3244.
39. Diekman T, Demacker PN, Kastelein JJP, et al.: Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998, 83:1752-1755.
40. Duntas LH, Mantzou E, Koutras DA: Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002, 12:1003-1007.
41. Ineck BA, Ng TMH: Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother 2003, 37: 25-730.
42. Ladenson PW, Singer PA, Ain KB, et al.: American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Int Med 2000, 160:1573-1575.
43. Danese MD, Powe NR, Sawin Ct, Ladenson PW: Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996, 276:285-292.
44. Thompson PD, Clarkson P, Karras RH: Statin-associated myopathy. JAMA 2003, 289:1681-1690.
45. Surks MI, Ortiz E, Daniels GH, et al.: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004, 291:228-238.
46. Azezli A, Ozbey N, Taskale, et al.: The comparison of L-thyroxine versus L-thyroxine and statin combinations in lipid status in patients with subclinical hypothyroidism. J Endocrinol Invest 2000, 23:39.
47. Baxter JD, Webb P, Grover G, Scanlan TS: Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004, 15:154-157.
48. Grover GJ, Mellström K, Ye L, et al.: Selective thyroid hormone receptor-b activation: a strategy for reduction of weight, cholesterol, and lipoprotein(a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003, 100:10067-10072.
49. Taylor AH, Stephan ZF, Steele RE, Wong NCW: Beneficial effects of a novel thyromimetic in lipoprotein metabolism. Mol Pharmacol 1997, 52:542-547.